Pharmafile Logo

skin diseases

- PMLiVE

Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer

Around 195,000 people globally will be treated for this form of lung cancer in 2026

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

Some patients found the treatment reduced itch and sleep disturbance within just two days

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Kyowa Kirin and University Hospitals Birmingham announce new survival data in rare disease study

The study demonstrated meaningful survival benefits for patients with cutaneous T cell lymphoma

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

The inflammatory skin condition affects over 26 million people in the US

- PMLiVE

Eli Lilly/Almirall’s Ebglyss shows promise in atopic dermatitis patients with darker skin tones

The inflammatory skin condition occurs in approximately 7.3% of adults in the US

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links